How To Reduce Batch-To-Batch Variation In Cell Therapy Manufacturing | Audience Q&A

An excerpt from Cell & Gene Live's How To Reduce Batch-to-Batch Variation In Cell Therapy Manufacturing. At the end of the presentation, Omkar Kowlaker, Ph.D., Head of Manufacturing and Supply Chain at NextGen Therapies Consulting at Deloitte and Donna Rill, Chief Technology Officer at Triumvira Immunologics, spent some time answering questions from our audience. We covered regulatory concerns, internal process control, and more.